29th Jun 2009 17:27
June 29 2009
HENDERSON MORLEY PLC
(AIM: HML)
("Henderson Morley" or "the Company")
Close of Offer, and Directors Holdings
At the close of the Offer at 12 noon today, subscriptions had been received for 250,505,000 new Ordinary Shares in the Offer, raising c£625,000 (gross) for the Company. At a Board meeting held today 283,085,500 new Ordinary Shares were allotted (which includes 22,580,500 bonus shares issued to existing shareholders who successfully subscribed in the Offer, and 10,000,000 shares issued in lieu of underwriting commission in relation to the Offer).
Application has been made for all these new ordinary shares to be admitted to AIM.
Admission is expected to take place on 3 July 2009.
The Company now has 1,004,347,463 ordinary shares in issue.
As a result of the above allotment of shares, the following directors' holdings are as follows:
|
Name
|
No of Shares acquired
|
Resultant Holding
|
%
|
|
|
|
|
|
|
Mr A Knight
|
18,765,000
|
129,918,764
|
12.94
|
|
Dr I Pardoe
|
17,000,000
|
91,727,751
|
9.13
|
|
C Pate
|
2,400,000
|
2,650,000
|
0.26
|
Mr Knight subscribed for 14,150,000 shares in the Offer at 0.25p per share. He also received 1,415,000 shares as bonus shares to which he is entitled as an existing shareholder, and 3,200,000 shares in lieu of participating in the underwriting of the Offer
Dr Pardoe subscribed for 14,000,000 shares in the Offer at 0.25p per share. He also received 1,400,000 shares as bonus shares to which he is entitled as an existing shareholder, and 1,600,000 shares in lieu of participating in the underwriting of the Offer
Mr Pate subscribed for 2,000,000 shares in the Offer at 0.25p per share. He also received 200,000 shares as bonus shares to which he is entitled as an existing shareholder, and 200,000 shares in lieu of participating in the underwriting of the Offer
Commenting on the close of the Offer Andrew Knight, Chairman of Henderson Morley, said: "We are delighted with the response to the Share Offering and would like to thank all those who participated, especially the existing shareholders who have shown their continued support.
"We believe that the next twelve months will be hugely significant for the Company with the potential sale of the human element of ICVT, the anticipated results of the Koi Herpes Vaccine and the restructuring of the Company towards becoming a pure play vaccine company."
--END--
ENQUIRIES:
HENDERSON MORLEY PLC 0121 442 4600
Andrew Knight, Chairman
BISHOPSGATE COMMUNICATIONS LTD 0207 562 3350
(Public Relations)
Maxine Barnes Gemma O'Hara
BREWIN DOLPHIN INVESTMENT BANKING 0845 213 4726
(Nominated Adviser)
Neil Baldwin
RIVINGTON STREET CORPORATE FINANCE LTD 020 7562 3380
(Broker)
Monisha Varadan
Related Shares:
HML.L